林业发展局和疾病防治中心建议,由于严重的副作用,60岁以上的人暂停使用Ixchiq疫苗。 FDA and CDC recommend pausing use of chikungunya vaccine Ixchiq in people aged 60+ due to serious side effects.

FDA 和 CDC 建议暂停在 60 岁及以上的人群中使用 Valneva 的基孔肯雅热疫苗 Ixchiq，因为 62 至 89 岁的接种者报告了严重的不良事件，包括神经系统和心脏问题。 The FDA and CDC recommend pausing the use of Valneva's chikungunya vaccine, Ixchiq, in people aged 60 and older due to serious adverse events, including neurological and cardiac issues, reported in recipients aged 62 to 89. 截至5月7日,共发生了17起严重事件,其中包括两起死亡事件。 There have been 17 serious events, including two deaths, as of May 7. 仍然建议为18至59岁有接触风险的人提供疫苗,而林业发展局则对年龄较大的年龄组进行新的福利风险评估。 The vaccine remains recommended for those aged 18 to 59 at risk of exposure, while the FDA conducts a new benefit-risk assessment for the older age group.